Medical doctor touching virtual interface button of healthcare application
Medical doctor touching virtual interface button of healthcare application, concept about health technology background

Precision cancer care company Syapse has announced it has entered a strategic alliance with pharmaceutical company Pfizer that will use real-world evidence to help advance research into effective cancer treatments and improve patient care. This newest deal is the third for Syapse engaging big pharma in a real-world data collaboration.

The collaboration with Pfizer will focus on molecular testing and how that affects patients’ care delivery within the healthcare setting and leverage the real-world data from Syapse’s network of health system partners.

“Pfizer is committed to using real-world evidence to improve cancer care and decision-making by healthcare providers,” said Chris Boshoff, M.D., Ph.D., chief development officer, Oncology, Pfizer Global Product Development in a press release. “We look forward to working with Syapse and its network of health system partners to better understand the treatment journeys of people living with cancer and develop evidence-based insights that can help improve outcomes.”

According to information provided by Syapse, the company’s goal is to build a learning health network for precision medicine that includes data from health systems in the U.S and abroad, along with other innovators in the space. It counts Advocate Aurora Health (Wisconsin), CommonSpirit Health (Colorado), Henry Ford Health System (Michigan), Providence St. Joseph Health (Alaska, California, Montana, New Mexico, Oregon, Texas and Washington), and Seoul National University Hospital (Korea) among its network of healthcare providers.

In addition to Pfizer, Syapse also struck similar real-world data collaborations with Roche in early 2018, and Amgen in May. One focus of the Roche partnership is to refine methods of gathering real-world data for measuring patient outcomes; the Amgen deal will focus on developing this evidence in areas of unmet need in the cancer space, while also using the data to help support its drug development efforts.

The new collaboration with Pfizer will examine the use of molecular diagnostics to help guide a patient’s care and therapeutic choices. It also continues to build on Syapse’s model of facilitating collaboration between health systems and life sciences companies to help accelerate the delivery of precision medicine.

“Pfizer is on the forefront of utilizing real-world data to improve the lives of patients worldwide and we are pleased to work with them to unlock evidence and insights that can help improve patient care and accelerate the availability of new treatments,” said Ken Tarkoff, CEO of Syapse in a prepared statement. “To realize the potential of precision medicine all of the stakeholders in the healthcare ecosystem need to work together. At Syapse, we are proud of the collaborations we are facilitating between life science companies and health systems and we are committed to translating this work into solutions that help providers deliver consistent, cost-effective, patient-centered cancer care.”

Also of Interest